The drug that is injected once a year for osteoporosis is usually said to be zoledronic acid. Zoledronic acid belongs to the 3rd generation of bisphosphonates and is now increasingly widely used in anti-osteoporosis treatment. Intravenous zoledronic acid injections enter the bloodstream directly, and over the course of 1 year after the injection, zoledronic acid and osteoclasts progressively bind and work together, and are slowly removed from the bone surface, so that the effects are sustained over that 1 year period. Adverse reactions include flu-like symptoms, fever, headache, nausea, bone pain, myalgia, and arthralgia. Contraindicated in patients with hypersensitivity to any component of zoledronic acid, in patients with hypocalcemia, in patients with severe renal impairment with creatinine removal rates less than <35 mI/min, and in pregnant and lactating women. After the diagnosis of osteoporosis is confirmed, the drug should be used in regular hospitals under the guidance of doctors, and if any discomfort occurs, it should be consulted promptly.